Twist Bioscience/$TWST
1D1W1MYTD1Y5YMAX
Capital at risk
About Twist Bioscience
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
- Ticker
- $TWST
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 979
- Headquarters
- South San Francisco, United States
- Website
- www.twistbioscience.com
Twist Bioscience Metrics
BasicAdvanced
$8B
-
-$2.23
2.16
-
Price and volume
Market cap
$8B
Beta
2.16
52-week high
$155.44
52-week low
$23.30
Average daily volume
1.7M
Financial strength
Current ratio
2.672
Quick ratio
1.98
Long term debt to equity
22.426
Total debt to equity
24.362
Profitability
EBITDA (TTM)
-115.282
Gross margin (TTM)
51.97%
Net profit margin (TTM)
-31.66%
Operating margin (TTM)
-31.91%
Effective tax rate (TTM)
-0.64%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-13.09%
Return on equity (TTM)
-29.59%
Valuation
Price to revenue (TTM)
18.21
Price to book
18.01
Price to tangible book (TTM)
18.01
Price to free cash flow (TTM)
-80.055
Free cash flow yield (TTM)
-1.25%
Free cash flow per share (TTM)
-1.6
Growth
Revenue change (TTM)
19.19%
Earnings per share change (TTM)
54.97%
3-year revenue growth (CAGR)
22.40%
3-year earnings per share growth (CAGR)
-15.50%
What the Analysts think about Twist Bioscience
Analyst ratings (Buy, Hold, Sell) for Twist Bioscience stock.
Analyst projections of the future price of Twist Bioscience stock.
Bulls say / Bears say
Twist delivered record Q3 FY26 revenue of $118.4 million, up 23% year-over-year, marking its 14th consecutive quarter of sequential growth and outpacing prior guidance (SEC Filings).
Gross margin expanded to 52.8% in Q3 FY26, up approximately 120 basis points sequentially, reflecting improved operational efficiency and favorable product mix (SEC Filings).
Management raised full-year FY26 revenue guidance to $456 million–$457 million (a $12 million midpoint increase) while reiterating expected adjusted EBITDA breakeven in Q4 FY26, demonstrating confidence in its growth trajectory and path to profitability (SEC Filings).
Despite strong topline growth, Twist reported a GAAP net loss of $35.1 million (–$0.56 per share) in Q3 FY26 versus net income of $20.4 million a year earlier, underscoring ongoing unprofitability and earnings volatility (SEC Filings).
Adjusted EBITDA remained negative at $11.3 million in Q3 FY26, compared with an $8.0 million loss in Q3 FY25, indicating that the company’s path to sustained profitability remains uncertain despite rising revenue (SEC Filings).
The company agreed to a $17.1 million investor settlement to resolve allegations it misled investors about synthetic DNA quality and manufacturing automation; while insurers are expected to cover most of the liability, final court approval is still pending and could pose reputational and financial risks (Bloomberg Law).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2026.
Twist Bioscience Financial Performance
Revenues and expenses
Twist Bioscience Earnings Performance
Company profitability
Upcoming events
No upcoming events
Twist Bioscience News
AllArticlesVideos
Funds containing Twist Bioscience
AllUSDEURGBP
Fund name | Fund size | $TWST weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.57% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.57% |
iShares Healthcare Innovation£DRDR | £1B | 0.57% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.39% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.39% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.